ecrin-mdr-crcClinical2022IPD Sharing (as of September 2023): NoCarcinoid Intestine TumorCarcinoid TumorCarcinoid Syndrome DiarrheaDiarrheaCarcinoid Tumor of Cecum0 SINDROME CARCINOIDECarcinoid SyndromeNeoplasmsCarcinoid Tumor of PancreasMalignant Carcinoid SyndromeCarcinoid Tumor of IleumCarcinoidPancreatic NeoplasmsCarcinoid Tumor of LiverSerotonin SyndromeCarcinoid Intestine TumorCarcinoid TumorCarcinoid Syndrome DiarrheaCarcinoid Tumor Of PancreasCarcinoid Tumor Of LiverDiarrheaCarcinoid SyndromeNeoplasms0 Sindrome CarcinoideMalignant Carcinoid SyndromeCarcinoid Tumor Of CecumCarcinoid Tumor Of IleumCarcinoidPancreatic NeoplasmsSerotonin SyndromeInterventionalhttps://newmdr.ecrin.org/Study/2726811ArgentinaHungaryCzechiaUnited StatesUnited KingdomSpainRussiaCanadaAustriaBelgiumBrazilPolandItalyMexicoIsraelFranceBulgariaSerbiaPeruGermany6CRN00808Somatostatin agonistLanreotideOctreotideNeuroendocrine tumorPaltusotineECRIN MDRRecruitingfalseStudy to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid SyndromeThe purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.2022-06-152726811NCT053616682022-000762-18PER-049-22